Bioequivalence studies with anti-TNF biosimilars

References

• European Medicine Agency: Biosimilars in the EU. Information guide for healthcare professionals. [Access on 2018 Jul 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
   Google Scholar
• IQVIA Institute for Human Data Science: 2018 and beyond: outlook and turning points. [Access on 2018 Jul 26]. Available from: https://www.iqvia.com/institute/reports/2018-and-beyond-outlook-and-turning-points
   Google Scholar
• US Food and Administration Biosimilar and Interchangeable Products. [Access on 2018 Aug 1]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm#biological
   Google Scholar
• IQVIA Institute for human data science: outlook for global medicines through 2021. Balancing cost and value. [Access on 2018 Jul 26]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-outlook-for-medicines-through-2021.pdf
   Google Scholar
• Quintiles IMS: The impact of biosimilar competition in Europe. [Access on 2018 Jul 26]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf
   Google Scholar
• Severs M, Oldenburg B, van Bodegraven AA, et al. Initiative of Crohn´s and Colitis. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11:289–296.
   PubMed Web of Science ®Google Scholar
• Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–5117.
   PubMed Web of Science ®Google Scholar
• Chingcuanco F, Segal JB, Kim SC, et al. Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: a systematic review. Ann Intern Med. 2016;165:565–574.
   PubMed Web of Science ®Google Scholar
• US Food and Administration: scientific consideration in demonstrating biosimilarity to a reference product. Guidance for industry. [Access on 2018 Jul 26]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf
   Google Scholar
• Australian Government. Department of health therapeutic goods administration. Biosimilar medicines regulation. [Access on 2018 Aug 26]. Available from: https://www.tga.gov.au/sites/default/files/biosimilar-medicines-regulation.pdf
   Google Scholar
• World Health Organisation. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs), Annex 2. 2016. Technical Report Series. No. 1004. [Access on 2018 Aug 26]. Available from: http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1
   Google Scholar
• World Health Organisation. Guidelines on evaluation of monoclonal antibodies as Similar Biotherapeutic Products (SBPs), Annex 2. 2009. Technical Report Series. No. 977. Available from: http://www.who.int/biologicals/biotherapeutics/WHO_TRS_1004_web_Annex_2.pdf?ua=1
   Google Scholar
• Junk SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima®. Mabs. 2014;6:1163–1177.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Inflectra: EPAR-Public Assessment Report. [Access on 2018 Jul 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf
   Google Scholar
• European Medicine Agency. Remsima: EPAR-Public Assessment Report. [Access on 2018 Jul 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf
   Google Scholar
• Gabani T, Deiana S, Annese V. CT-P13: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:1653–1661.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Flixabi®: EPAR-Public Assessment Report. [Access on 2018 Jul 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004020/WC500208358.pdf
   Google Scholar
• European Medicine Agency. Zessly®: EPAR-Public Assessment Report. [Access on 2018 Jul 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004647/WC500249649.pdf
   Google Scholar
• Lee C, Jeong M, Lee JJ, et al. Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. MAbs. 2017;9:968–977.
   PubMed Web of Science ®Google Scholar
• Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade®. MAbs. 2017;9:365–383.
   Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346–354.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;2(18):82.
   Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–363.
   PubMed Web of Science ®Google Scholar
• Shin D, Kim Y, Kim YS, et al. A randomized, phase i pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects. BioDrugs. 2015;29:381–388.
   PubMed Web of Science ®Google Scholar
• Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade® in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58–64.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology (Oxford). 2017;56:1771–1779.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency.Guideline on similar biological medicinal products containing monoclonal antibodies—nonclinical and clinical issues [EMA/CHMP/BMWP/403543/2010]. 2012.
   Google Scholar
• Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol. 2014;28:465–471.
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22–31.
   PubMed Web of Science ®Google Scholar
• Gargallo CJ, Lué A, Gomollón F. Biosimilars in inflammatory bowel disease. Minerva Med. 2017;108:239–254.
   PubMed Web of Science ®Google Scholar
• Kim YH, Ye BD, Pesegova M et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: early efficacy and safety results. Paper presented at: 12th Congress of ECCO; 2017; Barcelona, Spain.
   Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. Biodrugs. 2017;31:299–316.
   PubMed Web of Science ®Google Scholar
• Bridges SL Jr, White DW, Worthing AB, et al. The science behind biosimilar. Arthritis Rheumatol. 2018;70:334–344.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Baltrukonis DJ, Bhattacharya I, et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol. 2018;192:348–365.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency: Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. [Access on 2018 Aug 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf
   Google Scholar
• Smolen JS, Choe J, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77:234–240.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Benhar I. te al. Cross-immunogenicity: antibodies to infliximab in Remicade®-treated patiens with IBD similarly recognise the biosimilar Remsima®. Gut. 2016;65:1132–1138.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguello MB, Maguregui A, Ruiz Del Agua A, et al. Antibodies to infliximab in Remicade®-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016;75:1693–1696.
   PubMed Web of Science ®Google Scholar
• Goncalves J, Santos M, Arcurio R, et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment Pharmacol Ther. 2018;48(5):507–522.
   Web of Science ®Google Scholar
• Fiorino G, Ruiz-Aguello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:601–606.
   PubMed Web of Science ®Google Scholar
• Gisbert JP. Chaparro M Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: can it be recommended? A systematic review. Gastroenterol Hepatol. 2018;41:389–405.
   PubMed Web of Science ®Google Scholar
• Chow SC. Assessing biosimilarity and interchangeability of biosimilar products. Stat Med. 2013;32:361–363.
   PubMed Web of Science ®Google Scholar
• Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Effectiveness and safety of CT-P13 (biosimilar infliximab) inpatients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci. 2017;62:1305–1312.
   PubMed Web of Science ®Google Scholar
• Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol. 2017;29:1290–1295.
   PubMed Web of Science ®Google Scholar
• Bettey M, Downey L, Underhill C, et al. Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. J Crohns Colitis. 2016;10(Suppl. 1):DOP029.
   Google Scholar
• Buer LC, Moum BA, Cvancarova M, et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11:297–304.
   PubMed Web of Science ®Google Scholar
• Díaz Hernández L, Rodríguez González GE, Vela González M, et al. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months. J Crohns Colitis. 2016;10(Suppl. 1):P449.
   PubMed Web of Science ®Google Scholar
• Rodríguez Glez GE, Díaz Hernández L, Morales Barrios JA, et al. Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year. J Crohns Colitis. 2017;11(Suppl. 1):P629.
   Google Scholar
• Eberl A, Huoponen S, Pahikkala T, et al. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Scand J Gastroenterol. 2017;24:1–6.
   Google Scholar
• Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO Cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23:233–243.
   PubMed Web of Science ®Google Scholar
• Guerrero Puente L, Iglesias Flores E, Benitez JM, et al. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission. Gastroenterol Hepatol. 2017;40:595–604.
   PubMed Web of Science ®Google Scholar
• Hamanaka S, Nakagawa T, Koseki H, et al. Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study. J Crohns Colitis. 2016;10(Suppl. 1):P329.
   Google Scholar
• Hlavat´Y T, Krajcovicova A, Sturdik I, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases a one-year, single-centre retrospective study. Gastroenterol Hepatol. 2016;70:27–36.
   Google Scholar
• Jahnsen J, Kaasen Jorgensen K. Experience with biosimilar rinfliximab (Remsima®) in Norway. Dig Dis. 2017;35:83–90.
   PubMed Web of Science ®Google Scholar
• Jarzebicka D, Banaszkiewicz A, Plocek A, et al. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. J Crohns Colitis. 2015;10(Suppl. 1):P295.
   Google Scholar
• Jones ASC, Smith M. Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy. J Crohns Colitis. 2017;11(Suppl. 1):P527.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, inpatients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–1712.
   PubMed Web of Science ®Google Scholar
• Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951–956.
   PubMed Web of Science ®Google Scholar
• Kang B, Lee K, Choe YH. Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational study. Crohns Colitis. 2017;11(Suppl. 1):P542.
   Google Scholar
• Kolar M, Duricova D, Bortlik M, et al. Infliximab biosimilar (Remsima®) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis. 2017;35:91–100.
   PubMed Web of Science ®Google Scholar
• Nugent S, Nugent M, Mullane D, et al. EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience. Crohns Colitis. 2017;11(Suppl. 1):P430.
   Google Scholar
• Park SH, Kim YH, Lee JH, et al. study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl. 1):35–44.
   PubMedGoogle Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11:690–696.
   PubMed Web of Science ®Google Scholar
• Soret PA, Prieux-Klotz C, Avouac J, et al. Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experience. J Crohns Colitis. 2017;11(Suppl. 1):P471.
   Google Scholar
• Sieczkowska J, Jarzebicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease, preliminary observations. J Crohns Colitis. 2016;10:127–132.
   PubMed Web of Science ®Google Scholar
• Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–1293.
   PubMed Web of Science ®Google Scholar
• Strik A, van de Vrie V, van Megen Y, et al. Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn’s disease: a prospective study. J Crohns Colitis. 2017;11(Suppl. 1):P665.
   Google Scholar
• Suk YJ, Park DY, Kim YH, et al. Efficacy and safety of infliximab’s biosimilar (Remsima®) for IBD. J Crohns Colitis. 2015;10(Suppl. 1):P540.63.
   Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
   PubMed Web of Science ®Google Scholar
• Kay J, Winthrop KL. Pharmacotherapy: biosimilar switching-“To set a form upon desired change”. Nat Rev Rheumatol. 2017;13:391–392.
   PubMed Web of Science ®Google Scholar
• EMA. Amgevita: EPAR – Public assessment report. [Acces on 2018 Jul 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004212/WC500225277.pdf
   Google Scholar
• FDA. Drug approval package: Amjevita (adalimumab-atto). Medical review. [Acces on 2018 Aug 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000MedR.pdf
   Google Scholar
• Velayudhan J, Chen Y, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. Biodrugs. 2016;30:339–351.
   PubMed Web of Science ®Google Scholar
• Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76:526–533.
   PubMed Web of Science ®Google Scholar
• EMA. Cyltezo: EPAR – Public assessment report. [Acces on 2018 Aug 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004319/WC500238609.pdf
   Google Scholar
• Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Expert Opin Investig Drugs. 2016;25:1361–1370.
   PubMed Web of Science ®Google Scholar
• Cohen S, Klimiuk PA, Assudani D. Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results form Phase II open-labell clinical study (VOLTAIRE®-RL). Exper Opin Drug Deliv. 2018;15:545–548.
   PubMed Web of Science ®Google Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679–1687.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H. Costanzo A Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol. 2017;76:1093–1102.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77:914–921.
   PubMed Web of Science ®Google Scholar